Pharma Mar 将来の成長
Future 基準チェック /56
Pharma Mar利益と収益がそれぞれ年間31.8%と17.9%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に38% 30.1%なると予測されています。
主要情報
31.8%
収益成長率
30.12%
EPS成長率
| Biotechs 収益成長 | 22.3% |
| 収益成長率 | 17.9% |
| 将来の株主資本利益率 | 37.99% |
| アナリストカバレッジ | Good |
| 最終更新日 | 18 Jun 2026 |
今後の成長に関する最新情報
Recent updates
ナラティブの更新 • Jun 25
PHM: First Line Lung Cancer Maintenance Approvals Will Support Medium Term Upside
Analysts have reset their 12 month price target for Pharma Mar to €125, reflecting updated assumptions around a slightly higher discount rate, modestly stronger projected revenue growth and profit margins, and a marginally lower future P/E, while citing supportive recent Street research coverage. What’s in the News for Pharma Mar Zepzelca (lurbinectedin) did not meet the primary overall survival endpoint in the Phase III LAGOON confirmatory trial for relapsed metastatic small cell lung cancer, according to Jazz Pharmaceuticals and Pharma Mar.ナラティブの更新 • Jun 06
PHM: Asia Pacific Lung Cancer Approvals Will Drive Medium Term Upside Potential
Analysts have maintained their €125 price target on Pharma Mar, citing BTIG's recent bullish initiation and updated assumptions for slightly higher revenue, profit margins, and a modestly lower discount rate and P/E multiple. What's in the News European Commission approves Zepzelca (lurbinectedin) with atezolizumab (Tecentriq) as first-line maintenance therapy for adult patients with extensive-stage small cell lung cancer whose disease has not progressed after standard induction therapy, following a positive opinion from the EMA, based on the phase 3 IMforte trial (source: company announcement).ナラティブの更新 • May 21
PHM: Asia Pacific Lung Cancer Expansion Will Support Medium Term Upside Potential
Analysts have raised their price target on Pharma Mar from €118 to €125, citing new research that reflects updated assumptions on growth, profitability and future P/E expectations following fresh coverage with a bullish stance. Analyst Commentary Recent Street research coverage reflects a confident tone around Pharma Mar, with bullish analysts pointing to updated assumptions on growth, profitability and future P/E expectations as key supports for higher valuation ranges.分析記事 • May 09
Pharma Mar's (BME:PHM) Solid Profits Have Weak Fundamentals
Despite posting some strong earnings, the market for Pharma Mar, S.A.'s ( BME:PHM ) stock hasn't moved much. We did...分析記事 • Nov 07
There May Be Underlying Issues With The Quality Of Pharma Mar's (BME:PHM) Earnings
Pharma Mar, S.A.'s ( BME:PHM ) robust earnings report didn't manage to move the market for its stock. We did some...分析記事 • Nov 02
Pharma Mar, S.A. (BME:PHM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Pharma Mar, S.A. ( BME:PHM ) last week reported its latest third-quarter results, which makes it a good time for...分析記事 • Oct 29
Is Pharma Mar (BME:PHM) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Aug 03
Risks To Shareholder Returns Are Elevated At These Prices For Pharma Mar, S.A. (BME:PHM)
It's not a stretch to say that Pharma Mar, S.A.'s ( BME:PHM ) price-to-sales (or "P/S") ratio of 7.4x right now seems...分析記事 • Jun 16
Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.80
Pharma Mar, S.A.'s ( BME:PHM ) dividend will be increasing from last year's payment of the same period to €0.80 on 27th...分析記事 • May 23
Pharma Mar (BME:PHM) Has Announced That It Will Be Increasing Its Dividend To €0.80
Pharma Mar, S.A. ( BME:PHM ) will increase its dividend from last year's comparable payment on the 27th of June to...
新しいナラティブ • Mar 09
ZEPZELCA's EMA Submission Will Broaden Cancer Treatment Availability In Europe
Successful approval of ZEPZELCA in Europe and new markets could significantly boost PharmaMar’s future revenues, leveraging positive trial results.分析記事 • Mar 06
We Think Shareholders Should Be Aware Of Some Factors Beyond Pharma Mar's (BME:PHM) Profit
The latest earnings release from Pharma Mar, S.A. ( BME:PHM ) disappointed investors. Our analysis found several...分析記事 • Feb 13
There's Reason For Concern Over Pharma Mar, S.A.'s (BME:PHM) Massive 27% Price Jump
The Pharma Mar, S.A. ( BME:PHM ) share price has done very well over the last month, posting an excellent gain of 27...分析記事 • Oct 16
Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%
Pharma Mar, S.A. ( BME:PHM ) shares have continued their recent momentum with a 55% gain in the last month alone. The...分析記事 • Jul 28
Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Pharma Mar, S.A. ( BME:PHM ) shares have continued their recent momentum with a 27% gain in the last month alone...分析記事 • Jun 01
Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65
Pharma Mar, S.A.'s ( BME:PHM ) dividend will be increasing from last year's payment of the same period to €0.65 on 14th...分析記事 • May 28
Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry
Pharma Mar, S.A. ( BME:PHM ) shareholders would be excited to see that the share price has had a great month, posting a...分析記事 • Mar 03
Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Last week, you might have seen that Pharma Mar, S.A. ( BME:PHM ) released its annual result to the market. The early...分析記事 • Jan 25
Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Apr 28
Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Pharma Mar fair value estimate is €52.37 Pharma Mar is...分析記事 • Mar 08
We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability
Pharma Mar, S.A.'s ( BME:PHM ) lackluster earnings announcement last week disappointed investors. We think that they...分析記事 • Mar 05
Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)
Market forces rained on the parade of Pharma Mar, S.A. ( BME:PHM ) shareholders today, when the analysts downgraded...業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2028 | 407 | 204 | 155 | 207 | 8 |
| 12/31/2027 | 298 | 123 | 82 | 120 | 9 |
| 12/31/2026 | 210 | 48 | 49 | 85 | 8 |
| 3/31/2026 | 225 | 80 | 58 | 68 | N/A |
| 12/31/2025 | 221 | 75 | 44 | 53 | N/A |
| 9/30/2025 | 179 | 34 | 16 | 21 | N/A |
| 6/30/2025 | 189 | 42 | 1 | 9 | N/A |
| 3/31/2025 | 176 | 20 | -18 | -10 | N/A |
| 12/31/2024 | 175 | 26 | -9 | 6 | N/A |
| 9/30/2024 | 167 | 1 | -18 | 2 | N/A |
| 6/30/2024 | 159 | -2 | -30 | -10 | N/A |
| 3/31/2024 | 162 | 2 | -35 | -12 | N/A |
| 12/31/2023 | 158 | 1 | -29 | -13 | N/A |
| 9/30/2023 | 168 | 14 | -29 | -13 | N/A |
| 6/30/2023 | 175 | 21 | -14 | -1 | N/A |
| 3/31/2023 | 177 | 29 | N/A | N/A | N/A |
| 12/31/2022 | 196 | 49 | 29 | 38 | N/A |
| 9/30/2022 | 235 | 79 | N/A | N/A | N/A |
| 6/30/2022 | 233 | 85 | 41 | 48 | N/A |
| 3/31/2022 | 232 | 91 | N/A | N/A | N/A |
| 12/31/2021 | 230 | 93 | 18 | 26 | N/A |
| 9/30/2021 | 188 | 63 | N/A | N/A | N/A |
| 6/30/2021 | 200 | 67 | 19 | 24 | N/A |
| 3/31/2021 | 222 | 91 | 113 | 117 | N/A |
| 12/31/2020 | 270 | 137 | 276 | 279 | N/A |
| 9/30/2020 | 246 | 147 | 264 | 270 | N/A |
| 6/30/2020 | 214 | 124 | 255 | 259 | N/A |
| 3/31/2020 | 166 | 72 | 161 | 165 | N/A |
| 12/31/2019 | 86 | -9 | N/A | -24 | N/A |
| 9/30/2019 | 136 | -27 | N/A | -23 | N/A |
| 6/30/2019 | 84 | -37 | N/A | -12 | N/A |
| 3/31/2019 | 154 | -24 | N/A | -22 | N/A |
| 12/31/2018 | 109 | -17 | N/A | -17 | N/A |
| 9/30/2018 | 189 | -16 | N/A | -20 | N/A |
| 6/30/2018 | 128 | -20 | N/A | -22 | N/A |
| 3/31/2018 | 179 | -26 | N/A | -19 | N/A |
| 12/31/2017 | 159 | -28 | N/A | -1 | N/A |
| 9/30/2017 | 182 | -22 | N/A | 4 | N/A |
| 6/30/2017 | 186 | -18 | N/A | 9 | N/A |
| 3/31/2017 | 184 | -19 | N/A | 13 | N/A |
| 12/31/2016 | 181 | -24 | N/A | -8 | N/A |
| 9/30/2016 | 187 | -18 | N/A | N/A | N/A |
| 6/30/2016 | 188 | -10 | N/A | 5 | N/A |
| 3/31/2016 | 190 | -7 | N/A | N/A | N/A |
| 12/31/2015 | 194 | 7 | N/A | 11 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: PHMの予測収益成長率 (年間31.8% ) は 貯蓄率 ( 2.7% ) を上回っています。
収益対市場: PHMの収益 ( 31.8% ) はSpanish市場 ( 11.4% ) よりも速いペースで成長すると予測されています。
高成長収益: PHMの収益は今後 3 年間で 大幅に 増加すると予想されています。
収益対市場: PHMの収益 ( 17.9% ) Spanish市場 ( 6.6% ) よりも速いペースで成長すると予測されています。
高い収益成長: PHMの収益 ( 17.9% ) 20%よりも低い成長が予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: PHMの 自己資本利益率 は、3年後には高くなると予測されています ( 38 %)
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/26 00:30 |
| 終値 | 2026/06/26 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Pharma Mar, S.A. 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。12
| アナリスト | 機関 |
|---|---|
| Jaime Escribano | Banco Santander |
| Patricia Cifuentes | Bestinver Sociedad De Valores, S.A |
| Kambiz Yazdi | BTIG |